Table 1

Demographic characteristics of patients with rheumatic diseases treated with anti-TNF agents

N131
Sex (M/F)50/81
Mean±SD age (years)52±16
Mean±SD (median) years of follow-up during anti-TNF therapy2±1.4 (1.8)
HBV infection status
 Not HBV-exposed (HBsAg−, anti-HBc−, anti-HBs−)79 (60%)
 HBV-vaccinated (HBsAg−, anti-HBc−, anti-HBs+)19 (14.5%)
 Resolved HBV infection (HBsAg−, anti-HBc+, anti-HBs±)19 (14.5%)
 Chronic HBV infection (HBsAg+, anti-HBc+, anti-HBs−)14 (11%)
Underlying rheumatic disease
 Rheumatoid arthritis66 (50.4%)
 Spondyloarthropathies
  Ankylosing spondylitis32 (24.4%)
  Psoriatic arthritis21 (16%)
  Crohn-associated4 (3.1%)
  Undifferentiated7 (5.3%)
 Other1 (0.8%)
Type of anti-TNF therapy*
 Etanercept64 (38%)
 Adalimumab62 (37%)
 Infliximab43 (25%)
Anti-TNF agents used (n)
 198 (75%)
 228 (21%)
 35 (4%)
Anti-TNF discontinuation28 (22%)
 Inefficacy18
 Side effects/other reasons10
  • * Since some patients were treated with two or three agents, the cumulative number exceeds 100%.

  • Two infections, two neoplastic diseases, three deaths, three for various reasons.

  • anti-HBc, antibody against hepatitis B core antigen; anti-HBs, antibody to HBsAg; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; TNF, tumour necrosis factor.